mci 9038 has been researched along with Disease Models, Animal in 44 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.55) | 18.7374 |
| 1990's | 19 (43.18) | 18.2507 |
| 2000's | 15 (34.09) | 29.6817 |
| 2010's | 7 (15.91) | 24.3611 |
| 2020's | 1 (2.27) | 2.80 |
| Authors | Studies |
|---|---|
| Das, J; Kimball, SD; Lau, WF; Ogletree, ML; Reid, JA; Roberts, DG; Schumacher, WA; Seiler, SM; Wang, TC | 1 |
| Chang, CY; Chong, S; Das, J; Hall, SE; Han, WC; Iwanowicz, E; Kimball, SD; Lin, J; Malley, MF; Moquin, RV; Ogletree, ML; Reid, JA; Roberts, DG; Sack, JS; Schumacher, WA; Seiler, SM; Wang-Iverson, DB | 1 |
| Chattopadhyay, P; Deka, RC; Gogoi, D; Mukherjee, AK; Pal, A; Paul, S | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Boivin, G; Checkmahomed, L; Couture, C; Hamelin, MÈ; Jandrot-Perrus, M; Lê, BV; Venable, MC | 1 |
| Abekura, Y; Arai, D; Ikeda, H; Ishii, A; Miyamoto, S; Nishi, H; Tabata, Y | 1 |
| Cervera, A; Chamorro, Á; de la Rosa, X; Durduran, T; Justicia, C; Kristoffersen, AK; Planas, AM; Valdés, CP; Varma, HM | 1 |
| Ayer, R; Chen, W; Jadhav, V; Sugawara, T; Suzuki, H; Zhang, JH | 1 |
| Arnaout, O; Bendok, BR | 1 |
| Behrend, K; Cerny, V; Fuchs, C; Hung, O; Ladwig, E; Lehmann, C; Murphy, M; Pavlovic, D; Whynot, S; Zhou, J | 1 |
| Chen, B; Cheng, Q; Friedman, B; Lei, IF; Lyden, PD; Olson, ES; Pereira, B; Tsien, RY; Whitney, MA; Winkle, JA; Zhao, L | 1 |
| Cruz-González, I; López-Jiménez, R; Perez-Rivera, A; Yan, BP | 1 |
| Hoff, JT; Hua, Y; Keep, RF; Kitaoka, T; Xi, G | 1 |
| Kinoshita, M; Matsumori, A; Miyamoto, T; Ohashi, N; Sasayama, S | 1 |
| Kato, H; Kimura, S; Nakagawa, K; Nakagawa, M; Tsuji, H; Ukimura, N; Yamada, K; Yamada, Y; Yano, S | 1 |
| Honda, Y; Katsuta, H; Kiryu, J; Miyahara, S; Miyamoto, K; Nishijima, K; Nonaka, A; Tsujikawa, A; Yamashiro, K | 1 |
| Aoki, T; Matsuoka, N; Mihara, K; Moriguchi, A; Mutoh, S; Tojo, N | 1 |
| Bozic, M; Budihna, MV; Cerne, M; Drevensek, G; Peternel, L; Stalc, A; Stegnar, M; Urleb, U; Zega, A | 1 |
| Hua, Y; Karabiyikoglu, M; Keep, R; Xi, G | 1 |
| Nakashima, M; Nishiyama, H; Saniabadi, AR; Takiguchi, Y; Uematsu, T; Umemura, K | 1 |
| Kawai, H; Nakashima, M; Umemura, K | 1 |
| Berry, CN; Duval, N; Grosset, A; Lunven, C; O'Brien, DP; O'Connor, SE | 1 |
| Kawai, H; Sugimoto, J; Tamao, Y; Yuki, S | 1 |
| Berry, CN; Girard, D; Girardot, C; Lochot, S; Lunven, C; Visconte, C | 1 |
| Börjesson, I; Elg, M; Gustafsson, D; Lenfors, S; Teger-Nilsson, AC | 1 |
| Aoki, N; Fujimori, Y; Kawai, K; Nakamura, F; Omata, M; Sakamoto, Y; Tomaru, T; Uchida, Y | 1 |
| Aoki, N; Nakamura, F; Omata, M; Sakamoto, Y; Tomaru, T; Uchida, Y | 1 |
| Gustafsson, D; Lenfors, S | 1 |
| Giddings, JC; Kawano, M; Sasaki, Y; Watanabe, S; Yamamoto, J | 1 |
| Kambayashi, J; Kawasaki, T; Kim, DI; Sakon, M; Shibuya, T | 1 |
| Hara, T; Kunitada, S; Morishima, Y; Tanabe, K; Terada, Y | 1 |
| Berry, CN; Charles, MC; Ferrari, P; Girard, D; Girardot, C; Lechaire, I; Lunven, C; O'Brien, DP | 1 |
| Kikumoto, R; Tamao, Y | 1 |
| Hirayama, F; Kawasaki, T; Koshio, H; Matsumoto, Y; Sakai, Y; Sato, K; Taniuchi, Y | 1 |
| Horie, K; Kyogashima, M; Miyauchi, S; Mizuno, S; Onaya, J; Sunose, A | 1 |
| Berry, CN; Girard, D; Lecoffre, C; Lochot, S; Visconte, C | 1 |
| Jang, IK; Sabatine, MS; Tu, TM | 1 |
| Fukuda, K; Hosokawa, M; Kodama, M; Nakamura, H; Ohya, M; Onomura, M; Seino, Y; Tsukada, H | 1 |
| Endo, T; Huang, L; Izumi, K; Kawano, T; Nishitani, H; Ogawa, H; Ogushi, F; Sone, S; Sono, N; Tani, K; Ueno, J | 1 |
| Collen, D; Gold, HK; Imura, Y; Lesaffre, E; Stassen, JM; Vreys, I | 1 |
| Higashiyama, M; Kambayashi, J; Mori, T; Sakon, M; Tanaka, T; Tsujinaka, T; Yokota, M | 1 |
| Bush, LR; Connolly, TM; Mellott, MJ; York, SJ | 1 |
| Fitzgerald, DJ; Fitzgerald, GA | 1 |
| Breddin, HK; Haarmann, W; Krupinski, K; Markwardt, F | 1 |
2 review(s) available for mci 9038 and Disease Models, Animal
| Article | Year |
|---|---|
Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Animals; Antithrombins; Arginine; Disease Models, Animal; Drug Evaluation; Heparin; Hirudins; Humans; Peptide Fragments; Percutaneous Coronary Intervention; Pipecolic Acids; Randomized Controlled Trials as Topic; Recombinant Proteins; Sulfonamides; Thrombocytopenia; Thrombosis | 2012 |
Effect of argatroban, a selective thrombin inhibitor, on animal models of cerebral thrombosis.
Topics: Acute Disease; Animals; Anticoagulants; Antithrombin III Deficiency; Antithrombins; Arginine; Disease Models, Animal; Extracorporeal Circulation; Intracranial Embolism and Thrombosis; Pipecolic Acids; Rats; Sulfonamides | 1997 |
1 trial(s) available for mci 9038 and Disease Models, Animal
| Article | Year |
|---|---|
Effect of argatroban on trinitrobenzene sulfonic acid-induced colitis.
Topics: Analysis of Variance; Animals; Antithrombins; Arginine; Blood Coagulation Tests; Colitis; Disease Models, Animal; Heparin; Immunoenzyme Techniques; Infusion Pumps, Implantable; Leukotriene B4; Male; Nitrobenzenes; Peroxidase; Pipecolic Acids; Rats; Rats, Wistar; Sulfonamides; Sulfonic Acids | 2000 |
41 other study(ies) available for mci 9038 and Disease Models, Animal
| Article | Year |
|---|---|
Thrombin active site inhibitors: chemical synthesis, in vitro and in vivo pharmacological profile of a novel and selective agent BMS-189090 and analogues.
Topics: Animals; Binding Sites; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Fibrinolytic Agents; Humans; Mice; Nipecotic Acids; Rats; Serine; Serine Proteinase Inhibitors; Structure-Activity Relationship; Substrate Specificity; Thrombin; Thrombosis | 2002 |
Molecular design and structure--activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664.
Topics: Administration, Oral; Animals; Binding Sites; Crystallography, X-Ray; Dipeptides; Disease Models, Animal; Dogs; Drug Design; Drug Evaluation, Preclinical; Fibrinolytic Agents; Humans; Inhibitory Concentration 50; Macaca fascicularis; Mice; Serine Proteinase Inhibitors; Structure-Activity Relationship; Sulfonamides; Thrombin; Thrombosis | 2002 |
First Report of Plant-Derived β-Sitosterol with Antithrombotic, in Vivo Anticoagulant, and Thrombus-Preventing Activities in a Mouse Model.
Topics: Animals; Anticoagulants; Antithrombins; Catalysis; Disease Models, Animal; Female; Fibrinogen; Humans; Male; Mice; Plants; Platelet Aggregation Inhibitors; Sitosterols; Thrombin; Thrombosis | 2018 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Evaluation of anticoagulant agents for the treatment of human metapneumovirus infection in mice.
Topics: Animals; Anticoagulants; Arginine; Disease Models, Animal; Heparin; Metapneumovirus; Mice; Paramyxoviridae Infections; Pipecolic Acids; Sulfonamides; Survival Analysis; Treatment Outcome; Viral Load; Virus Replication; Warfarin | 2018 |
Development of a stent capable of the controlled release of basic fibroblast growth factor and argatroban to treat cerebral aneurysms: In vitro experiment and evaluation in a rabbit aneurysm model.
Topics: Animals; Arginine; Delayed-Action Preparations; Disease Models, Animal; Drug-Eluting Stents; Female; Fibroblast Growth Factor 2; Intracranial Aneurysm; Pipecolic Acids; Rabbits; Sulfonamides | 2019 |
Mannose-binding lectin promotes local microvascular thrombosis after transient brain ischemia in mice.
Topics: Animals; Antithrombins; Arginine; Brain Ischemia; Cerebrovascular Circulation; Disease Models, Animal; Fibrinogen; Infarction, Middle Cerebral Artery; Magnetic Resonance Imaging; Male; Mannose-Binding Lectin; Mice; Mice, Inbred C57BL; Mice, Knockout; Microcirculation; Pipecolic Acids; Reperfusion Injury; Sulfonamides; Thrombosis | 2014 |
Thrombin inhibition by argatroban ameliorates early brain injury and improves neurological outcomes after experimental subarachnoid hemorrhage in rats.
Topics: Animals; Anticoagulants; Arginine; Blood-Brain Barrier; Brain Edema; Cell Death; Disease Models, Animal; Male; Motor Activity; Pipecolic Acids; Rats; Rats, Sprague-Dawley; Recovery of Function; Subarachnoid Hemorrhage; Sulfonamides; Thrombin | 2009 |
Thrombin inhibition in subarachnoid hemorrhage.
Topics: Animals; Arginine; Disease Models, Animal; Humans; Pipecolic Acids; Platelet Aggregation Inhibitors; Subarachnoid Hemorrhage; Sulfonamides; Thrombin | 2009 |
Argatroban administration reduces leukocyte adhesion and improves capillary perfusion within the intestinal microcirculation in experimental sepsis.
Topics: Animals; Anticoagulants; Arginine; Blood Pressure; Capillaries; Cell Adhesion; Disease Models, Animal; Heart Rate; Intestines; Leukocytes; Male; Microcirculation; Microscopy, Video; Myography; Pipecolic Acids; Rats; Rats, Inbred Lew; Sepsis; Splanchnic Circulation; Sulfonamides; Time Factors; Vasodilation | 2010 |
Thrombin activity associated with neuronal damage during acute focal ischemia.
Topics: Amino Acids; Analysis of Variance; Animals; Antithrombins; Arginine; Avoidance Learning; Brain Injuries; Cell Death; Cognition Disorders; Disease Models, Animal; Factor X; Fibrinolysin; Gene Expression Regulation; In Situ Nick-End Labeling; Infarction, Middle Cerebral Artery; Male; Maze Learning; Motor Activity; Nerve Tissue Proteins; Pipecolic Acids; Pyrroles; Rats; Reaction Time; Receptor, PAR-1; Sulfonamides; Thrombin; Time Factors | 2012 |
Delayed argatroban treatment reduces edema in a rat model of intracerebral hemorrhage.
Topics: Animals; Antithrombins; Arginine; Brain; Brain Chemistry; Brain Edema; Cerebral Hemorrhage; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Hemoglobins; Infusions, Parenteral; Male; Microinjections; Pipecolic Acids; Rats; Rats, Sprague-Dawley; Stereotaxic Techniques; Sulfonamides; Time Factors; Treatment Outcome; Water | 2002 |
Thrombosis increases circulatory hepatocyte growth factor by degranulation of mast cells.
Topics: Animals; Anticoagulants; Arginine; Carotid Artery Thrombosis; Cell Degranulation; Disease Models, Animal; Disease Progression; Hepatocyte Growth Factor; Histamine; Male; Mast Cells; p-Methoxy-N-methylphenethylamine; Pipecolic Acids; Proto-Oncogene Proteins c-kit; Rats; Rats, Inbred Strains; Rats, Wistar; Reperfusion; Sulfonamides; Thrombin | 2002 |
Effects of argatroban and heparin on thrombus formation and tissue plasminogen activator-induced thrombolysis in a microvascular thrombosis model.
Topics: Animals; Arginine; Cricetinae; Disease Models, Animal; Drug Interactions; Fibrinolytic Agents; Heparin; Mesocricetus; Microcirculation; Partial Thromboplastin Time; Pipecolic Acids; Sulfonamides; Thrombolytic Therapy; Thrombosis; Time Factors; Tissue Plasminogen Activator | 2003 |
Argatroban attenuates leukocyte- and platelet-endothelial cell interactions after transient retinal ischemia.
Topics: Animals; Arginine; Blood Platelets; Cell Adhesion; Disease Models, Animal; Endothelium, Vascular; Gene Expression; Intercellular Adhesion Molecule-1; Ischemia; Leukocytes; Male; P-Selectin; Partial Thromboplastin Time; Pipecolic Acids; Platelet Aggregation Inhibitors; Prothrombin Time; Rats; Rats, Long-Evans; Reperfusion; Retina; Retinal Diseases; Retinal Vessels; RNA, Messenger; Sulfonamides; Thrombin; Treatment Outcome; Vascular Patency | 2003 |
Antithrombotic effects of FK419, a novel nonpeptide platelet GPIIb/IIIa antagonist, in a guinea pig photochemically induced middle cerebral artery thrombosis model: comparison with ozagrel and argatroban.
Topics: Animals; Antithrombins; Arginine; Blood Coagulation; Blood Platelets; Brain Ischemia; Disease Models, Animal; Guinea Pigs; Infarction, Middle Cerebral Artery; Male; Methacrylates; Pipecolic Acids; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Reperfusion Injury; Sulfonamides; Thromboxane B2 | 2004 |
Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models.
Topics: Administration, Oral; Animals; Anticoagulants; Arginine; Blood Coagulation Tests; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Fibrinolytic Agents; Injections, Subcutaneous; Male; Nadroparin; Phenylalanine; Pipecolic Acids; Rats; Rats, Wistar; Structure-Activity Relationship; Sulfonamides; Thrombin; Thrombophilia; Vena Cava, Inferior; Venous Thrombosis | 2005 |
Acute subdural hematoma: new model delineation and effects of coagulation inhibitors.
Topics: Animals; Anticoagulants; Arginine; Behavior, Animal; Disease Models, Animal; Diterpenes; Extremities; Fibrinolytic Agents; Ginkgolides; Hematoma, Subdural, Acute; Lactones; Male; Movement; Pipecolic Acids; Psychomotor Performance; Rats; Reproducibility of Results; Sulfonamides; Time Factors | 2005 |
Enhancement of thrombolytic efficacy of tissue-type plasminogen activator by adjuvants in the guinea pig thrombosis model.
Topics: Adjuvants, Pharmaceutic; Animals; Antithrombins; Arginine; Biphenyl Compounds; Disease Models, Animal; Drug Therapy, Combination; Endothelium, Vascular; Femoral Artery; Fibrinolytic Agents; Guinea Pigs; Heptanoic Acids; Indoles; Leukotriene Antagonists; Male; Microscopy, Electron, Scanning; Neutrophils; Pipecolic Acids; Platelet Aggregation Inhibitors; Receptors, Thromboxane; Recombinant Proteins; Sulfonamides; Thrombolytic Therapy; Thrombosis; Tissue Plasminogen Activator | 1994 |
Effect of argatroban on microthrombi formation and brain damage in the rat middle cerebral artery thrombosis model.
Topics: Animals; Antithrombins; Arginine; Arterial Occlusive Diseases; Cerebral Arteries; Disease Models, Animal; Intracranial Embolism and Thrombosis; Male; Pipecolic Acids; Rats; Rats, Wistar; Sulfonamides; Thrombin; Time Factors | 1995 |
Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin.
Topics: Angina, Unstable; Animals; Antithrombins; Arginine; Coronary Vessels; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Heparin; Male; Pipecolic Acids; Sulfonamides; Thrombin Time; Time Factors | 1996 |
Effects of a thrombin inhibitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model.
Topics: Animals; Antithrombins; Arginine; Brain Ischemia; Cerebral Arteries; Disease Models, Animal; Male; Pipecolic Acids; Rats; Rats, Sprague-Dawley; Sulfonamides | 1996 |
Antithrombotic activity of argatroban in experimental thrombosis in the rabbit.
Topics: Animals; Antithrombins; Arginine; Disease Models, Animal; Dose-Response Relationship, Drug; Femoral Artery; Infusions, Intravenous; Pipecolic Acids; Rabbits; Sulfonamides; Thrombosis | 1996 |
Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time.
Topics: Animals; Antithrombins; Arginine; Aspirin; Bleeding Time; Disease Models, Animal; Fibrinolytic Agents; Glycine; Heparin; Male; Molecular Weight; Pipecolic Acids; Piperidines; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Sulfonamides; Thrombolytic Therapy; Thrombophlebitis; Thrombosis | 1996 |
Induction of thrombolysis and prevention of thrombus formation by local drug delivery with a double-occlusion balloon catheter.
Topics: Angioscopy; Animals; Anticoagulants; Antithrombins; Arginine; Catheterization; Coronary Angiography; Coronary Thrombosis; Coronary Vessels; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Heparin; Injections, Intralesional; Pipecolic Acids; Plasminogen Activators; Sulfonamides; Thrombolytic Therapy; Treatment Outcome | 1996 |
Local treatment with an antithrombotic drug reduces thrombus size in coronary and peripheral thrombosed arteries.
Topics: Angioscopy; Animals; Antithrombins; Arginine; Batroxobin; Coronary Angiography; Coronary Thrombosis; Coronary Vessels; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Fibrinolytic Agents; Heparin; Infusions, Intravenous; Injections, Intralesional; Pipecolic Acids; Reference Values; Sulfonamides; Treatment Outcome | 1996 |
New model for in vivo studies of pharmacological interventions with endogenous fibrinolysis: effects of thrombin inhibitors.
Topics: Animals; Antithrombins; Arginine; Batroxobin; Boron Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolysis; Injections, Intravenous; Male; Oligopeptides; Pipecolic Acids; Rats; Rats, Sprague-Dawley; Sulfonamides; Thrombin | 1996 |
Adjuvant effect of argatroban on staphylokinase induced thrombolysis of platelet rich thrombi in rat mesenteric venules in vivo.
Topics: Animals; Antithrombins; Arginine; Blood Platelets; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Fibrinolysis; Fibrinolytic Agents; Image Processing, Computer-Assisted; Male; Metalloendopeptidases; Microscopy, Electron; Pipecolic Acids; Rats; Rats, Wistar; Recombinant Proteins; Sulfonamides; Thrombosis | 1997 |
In vivo evaluation of DX-9065a, a synthetic factor Xa inhibitor, in experimental vein graft.
Topics: Animals; Anticoagulants; Antithrombins; Arginine; Blood Vessel Prosthesis; Disease Models, Animal; Factor Xa Inhibitors; Graft Occlusion, Vascular; Heparin; Male; Microscopy, Electron, Scanning; Naphthalenes; Pipecolic Acids; Propionates; Rabbits; Sulfonamides; Thrombosis | 1996 |
Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
Topics: Animals; Anticoagulants; Antithrombin III; Arginine; Bleeding Time; Blood Coagulation; Disease Models, Animal; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Male; Naphthalenes; Peptide Hydrolases; Pipecolic Acids; Propionates; Rats; Rats, Wistar; Sulfonamides; Thrombin; Thrombosis | 1997 |
Ecarin Clotting Time: a predictive coagulation assay for the antithrombotic activity of argatroban in the rat.
Topics: Animals; Antithrombins; Arginine; Arteriovenous Shunt, Surgical; Blood Coagulation Tests; Disease Models, Animal; Male; Pipecolic Acids; Rats; Rats, Inbred Strains; Reference Values; Sulfonamides; Thrombophlebitis; Thromboplastin; Thrombosis; Treatment Outcome | 1998 |
Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis.
Topics: Administration, Oral; Animals; Anticoagulants; Antithrombin III; Arginine; Carotid Artery Thrombosis; Disease Models, Animal; Factor Xa Inhibitors; Heparin; Infusions, Intravenous; Naphthalenes; Pipecolic Acids; Piperidines; Rats; Sulfonamides | 1998 |
Effects of dermatan sulfate, a heparin cofactor II mediated thrombin inhibitor, on the endotoxin-induced disseminated intravascular coagulation model in the rat: comparison with low-molecular weight heparin, nafamostat mesilate and argathroban.
Topics: Animals; Arginine; Benzamidines; Dermatan Sulfate; Disease Models, Animal; Disseminated Intravascular Coagulation; Endotoxins; Guanidines; Heparin; Heparin Cofactor II; Male; Molecular Weight; Pipecolic Acids; Rats; Rats, Sprague-Dawley; Sulfonamides | 1998 |
Activity of a sub-cutaneously administered novel mixed micellar formulation of argatroban in rat and rabbit models of venous thrombosis.
Topics: Animals; Anticoagulants; Antithrombins; Arginine; Arteriovenous Shunt, Surgical; Bleeding Time; Blood Coagulation Tests; Carotid Arteries; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Compounding; Drug Evaluation, Preclinical; Hemostatics; Heparin; Injections, Subcutaneous; Male; Micelles; Pipecolic Acids; Rabbits; Rats; Sulfonamides; Thromboplastin; Venous Thrombosis | 2000 |
Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase.
Topics: Animals; Antithrombins; Arginine; Bleeding Time; Blood Flow Velocity; Blood Platelets; Disease Models, Animal; Drug Combinations; Drug Evaluation; Female; Femoral Artery; Fibrinolytic Agents; Heparin; Male; Partial Thromboplastin Time; Peptides; Peptides, Cyclic; Pipecolic Acids; Plasminogen Activators; Platelet Glycoprotein GPIIb-IIIa Complex; Rabbits; Reperfusion; Sulfonamides; Sulfoxides; Thrombosis; Tissue Plasminogen Activator | 2000 |
Thrombin promotes fibroblast proliferation during the early stages of experimental radiation pneumonitis.
Topics: Animals; Antithrombin III; Antithrombins; Arginine; Biological Assay; Bronchoalveolar Lavage Fluid; Cell Division; Cell Separation; Cells, Cultured; Disease Models, Animal; Fibroblasts; Growth Substances; Lung; Male; Pipecolic Acids; Radiation Injuries, Experimental; Radiation Pneumonitis; Rats; Rats, Wistar; Specific Pathogen-Free Organisms; Sulfonamides; Thrombin | 2001 |
Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model.
Topics: Animals; Antithrombins; Arginine; Aspirin; Blood Coagulation; Cricetinae; Disease Models, Animal; Drug Synergism; Femoral Vein; Fibrinolytic Agents; Hemostasis; Heparin; Injections, Intravenous; Male; Peptides, Cyclic; Pipecolic Acids; Platelet Aggregation Inhibitors; Platelet Count; Sulfonamides; Sulfoxides; Thrombosis | 1992 |
The effect of heparin on multiple organ failure and disseminated intravascular coagulation in a sepsis model.
Topics: Animals; Antithrombins; Arginine; Blood Coagulation; Disease Models, Animal; Disseminated Intravascular Coagulation; Heparin; Infections; Male; Multiple Organ Failure; Pipecolic Acids; Rabbits; Sulfonamides | 1990 |
Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis.
Topics: Animals; Arginine; Arterial Occlusive Diseases; Disease Models, Animal; Dogs; Femoral Artery; Hemodynamics; Male; Pipecolic Acids; Recurrence; Regional Blood Flow; Sulfonamides; Thrombin; Thrombin Time; Thrombolytic Therapy; Thrombosis; Tissue Plasminogen Activator | 1990 |
Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator.
Topics: Animals; Antithrombins; Arginine; Coronary Disease; Coronary Thrombosis; Disease Models, Animal; Dogs; Phospholipases; Phospholipases A; Pipecolic Acids; Platelet Aggregation; Reperfusion; Sulfonamides; Thrombin; Tissue Plasminogen Activator | 1989 |
Antithrombotic effects of three thrombin inhibitors in a rat model of laser-induced thrombosis.
Topics: Animals; Antithrombins; Arginine; Disease Models, Animal; Hirudins; Humans; Injections, Intravenous; Lasers; Light Coagulation; Pipecolic Acids; Rats; Rats, Inbred Strains; Sulfonamides; Thrombosis | 1989 |